Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Breast cancer can be reversed in laboratory mice, scientists report

04.11.2003


Findings provide new molecular drug targets, validate transgenic mouse models



Breast cancer researchers have demonstrated for the first time that it is possible to block genetic switches in mice that turn cancer on and off — thus preventing and even reversing breast cancer in the animals. The findings, reported Sunday morning at the 24th Congress of the International Association for Breast Cancer Research, suggest potential new molecular targets for drugs to prevent and potentially eradicate breast cancer in humans.

“It’s enormously gratifying,” said conference director Robert Cardiff, professor of pathology at UC Davis School of Medicine and Medical Center and an author of the research. “Our findings suggest paths forward that may help us alter the biological path of breast cancer and more successfully treat — and even potentially prevent — this cancer in humans.”


In new research reported by a team of scientists from Canada, Switzerland and UC Davis, investigators demonstrated that removing a single gene known as beta-1 integrin prevented or halted breast cancer growth in laboratory mice. Beta-1 integrin is a principal regulator of normal breast tissue growth and survival, but if the gene malfunctions, it can directly initiate breast tumors. The new work demonstrates that knocking out the beta-1 integrin gene prevents cancer-prone mice from developing breast tumors, and halts further tumor growth in mice that have already developed breast cancer.

“This study shows that it is absolutely essential to have the beta-1 integrin gene present in order for mammary gland tumors to develop. We now have a good target for biological drug development, and the challenge is to develop an agent that can block its activity,” said William J. Muller, professor of biochemistry at McGill University in Montreal and a lead investigator of the study.

In a related presentation, researchers from the University of Pennsylvania reported on a series of experiments using a novel mouse model of human breast cancer, one that enables scientists to turn oncogenes — genes that can cause cancer — on or off at will. A triggering agent, in this case the antibiotic doxycycline, throws the switch on or off. Scientists used the approach to test four oncogenes: c-myc, Neu, Wnt1, and v-Ha-Ras. When any one of the oncogenes was turned on, the transgenic mice developed extremely aggressive mammary tumors; in many cases, the tumors metastasized to the lungs. When the gene was turned off, many of the breast tumors — including many of the most aggressive and advanced cancers — regressed to the point that they no longer could be detected by physical examination, magnetic resonance imaging (MRI) or positron emission tomography (PET) scans.

“We’re extremely encouraged that we have been able to demonstrate in laboratory animals that we can make mammary cancers essentially disappear by reversing just one mutation,” said Lewis A. Chodosh, associate professor at the Abramson Family Cancer Research Center at the University of Pennsylvania and lead author of the study.
“This suggests that, with appropriate therapies that target the genes used in this study, we might be able to cause tumors to regress and improve substantially, even those that are quite advanced.”

However, even though many of the tumors in the transgenic mice went into complete remission, a substantial number of the cancers spontaneously recurred over periods of up to a year, Chodosh reported.

This finding is important since it replicates the natural history of human breast cancer — many women, after apparently successful treatment, harbor residual tumor cells that eventually give rise to tumor recurrences that ultimately may result in death. Some of these residual cells can remain for decades. No previous laboratory mouse model has successfully replicated this feature of human breast cancer cells.

“The next critical step is to figure out the mechanisms that some tumors use to escape these treatments,” Chodosh said. “We believe these mouse models will help us to do exactly that.”

Founded in the mid 1950s, the International Association for Breast Cancer Research is an international community of scientists focused on the important issues in modern breast cancer research. The 24th IABCR Congress, focused on preclinical research using mouse models of human breast cancer, is sponsored by UC Davis Cancer Center, the Office of Women’s Health of the U.S. Department of Health and Human Services, the California Breast Cancer Research Program, and the National Cancer Institute’s Mouse Models of Human Cancers Consortium and Specialized Programs of Research Excellence.

Claudia Morain | UC Davis Health System
Further information:
http://cme.ucdmc.ucdavis.edu/iabcr.htm
http://news.ucdmc.ucdavis.edu
http://cme.ucdmc.ucdavis.edu/Confrnce/IABCR/reversed.html

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>